Key result
Single-dose intracoronary eptifibatide during PCI resulted in similar rates of major adverse events within 24 hours compared to control (P>0.05).
Why the study?
Does single-dose intracoronary eptifibatide improve immediate clinical outcomes in patients undergoing PCI with stent implantation?
RCT (n=207)
randomized
Does single-dose intracoronary eptifibatide improve immediate clinical outcomes in patients undergoing PCI with stent implantation?
Single-dose intracoronary eptifibatide during PCI did not significantly reduce the immediate (24-hour) rates of major adverse cardiovascular events compared to control.
No immediate benefit from single-dose intracoronary eptifibatide during PCI; leaves open optimal dosing, timing, and longer-term effects.
Background: The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation. Materials and Methods: In an interventional study, patients undergoing percutaneous coronary intervention (PCI) were randomized into either the eptifibatide ( n = 100) or the control ( n = 107) group. In each group, demographic and clinical characteristics such as cardiac death, stent thrombosis (ST), myocardial infarction (MI), rates of target lesion and vessel revascularization, cerebral vascular accident (CVA), and emergency coronary artery bypass grafting (CABG) were recorded. Results: The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P > 0.05 considered significant for all comparisons. Conclusion: There were no statistical differences between the clinical outcomes of groups administered with single-dose intracoronary eptifibatide and control groups among patients undergoing PCI during stent implantation.
No takes yet. Share an insight, caveat, or question.
Shariati et al. (2016) conducted an RCT in Percutaneous coronary intervention (PCI) (n=207). Eptifibatide vs. Control was evaluated on Major adverse events (mortality, stent thrombosis, myocardial infarction, target lesion revascularization, target vessel revascularization, CVA, and emergency CABG) (p=>0.05). Single-dose intracoronary eptifibatide during PCI resulted in similar rates of major adverse events within 24 hours compared to control (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: